Depomed — Assertio Therapeutics — Investor Presentation (September 2018)
22 slides from Depomed's investor presentation, Sep 13, 2018
Slide 1: About this Presentation
About this Presentation The statements that are not historical facts contained in this presentation are forward-looking statements including, but not limited to, statements relating to the commercialization of Gralise, CAMBIA, and Zipsor, royalties associated with Collegium’s commercialization of NU
Slide 2: New Name, Renewed Mission: Advance Patient Care in Neurology, Orphan & Specialty Medicines
New Name, Renewed Mission: Advance Patient Care in the Company’s Core Areas of Neurology, Orphan & Specialty Medicines 3 Assertio Therapeutics, Inc. (Assertio) is a new name that reflects a new business strategy, mission, vision and values Established new headquarters in Lake Forest, IL Transformed
Slide 3: Principles Guiding the Way We Do Business
4 Principles Guiding the Way We Do Business Maintain a Strong NUCYNTA Franchise, Grow Our Neurology Business and Build a New Orphan/Specialty Business Leverage Opportunities In a Changing Market Place, Must be Able to Respond Quickly to Drive Superior Performance Committed to Putting the Patient Fir
Slide 4: A Clear Strategy for Growth
A Clear Strategy for Growth 5 Execution of Three-Pillar Growth Strategy Transforms Company MAINTAIN a Strong/Profitable NUCYNTA® Franchise GROW Neurology Business BUILD a New Orphan/Specialty Business Commercialization agreement with Collegium Pharmaceutical Amended agreement for CAMBIA® line extens
Slide 5: Transformation is Well Underway to Leaner, Faster Moving Company
6 Transformation is Well Underway to Leaner, Faster Moving, More Entrepreneurial Company TRANSFORMATION: Exit Opioid Commercialization Full Year 2016 Full Year 2017 Full Year 2018 Estimate # of Employees(1) 490 434 122 Non-GAAP SG&A(2) $183 Million $188 Million $105 million(3) Adjusted EBITDA Per Em
Slide 6: Collegium Partnership Supports Strong/Profitable NUCYNTA Franchise
Collegium Partnership Supports Maintaining a Strong/Profitable NUCYNTA® Franchise 7 MAINTAIN Collegium and Assertio Share a Commitment to Putting the Patient First Related to second-quarter 2018 activity, the Company received $33.75 million in cash and recognized $31.20 million in revenue For the fi
Slide 7: Growing Our Neurology Business
Growing Our Neurology Business 8 GROW Q2 ’18: stabilized core neurology brands with positive sequential total prescription growth for the franchise; but more work to do with Gralise® Co-promotion with Allegis Pharmaceuticals and Zipsor® began in June Added approximately 30 new sales reps that focus
Slide 8: Neurology Portfolio with Extended Patent Exclusivity
Neurology Portfolio with Extended Patent Exclusivity *Amended existing license agreement for a new presentation of Cambia which, if approved by FDA, may provide patent protection through at least 2026 ASSERTIO LAUNCH Q4 2011 Q2 2012 Q1 2014 INDICATIONS Management of postherpetic neuralgia (PHN) Mild
Slide 9: Key Focus Next Six Months: Grow Gralise
Key Focus Next Six Months Grow Gralise® 10 Reduced total call targets from 7,000 to 6,000 Increased call frequency to key Gralise prescribers; ~4,000 high-quality prescribers Gralise has strong managed-care coverage, >75 percent of commercial lives covered Better leverage covered lives Along with th
Slide 10: Cosyntropin (Synthetic ACTH Depot)
Cosyntropin (Synthetic ACTH Depot) First in a Portfolio of High-Value, High-Touch Orphan/Specialty Medicines Positioned to Address the Needs of Patients, Physicians and Payors 11 BUILD Plan to file for FDA approval of cosyntropin depot by year end 1st Indication (diagnostic - for suspected adrenocor
Slide 11: Cosyntropin (Synthetic ACTH Depot): A Real Alternative to Acthar Gel
12 Cosyntropin (Synthetic ACTH Depot) A Real Alternative to Acthar Gel Market dominated by Acthar Gel Assertio is committed to addressing key issues of the ACTH market while bringing a new, cost-effective synthetic ACTH alternative (cosyntropin depot) to market There have been multiple media and pol
Slide 12: The ACTH Market Is Valued at ~$1.3 Billion
13 The ACTH Market Is Valued at ~$1.3 Billion Acthar contributes the majority of the dollar sales, while Cortrosyn is used more frequently and in more patients Medicare/Medicaid is >65% of the ACTH market Projected ACTH Sales by Payment Type(1) ACTH Market TRx Patients Sales (Bn) Source: Symphony He
Slide 13: Cosyntropin Depot Trial Design in Infantile Spasms
14 Cosyntropin Depot Trial Design in Infantile Spasms Infantile Spasms Indication Investigational New Drug (IND) trial enrolling for infantile spasms The Pediatric Epilepsy Research Consortium (Kelly Knupp, MD, Principal Investigator) 15 sites enrolling ~400 patients Orphan drug status in infantile
Slide 14: Milestones in 2018 and Beyond
NUCYNTA® commercialization agreement: Closed agreement with Collegium Pharmaceutical Synthetic cosyntropin (Synthetic ACTH Depot): Commenced investigational new drug trial in infantile spasms Amended existing license agreement for CAMBIA line extension Announced new co-promotion agreement for Zipsor
Slide 15: Full-Year 2018 Financial Guidance
Full-Year 2018 Financial Guidance* 16 2018 Guidance Neurology Franchise Net Sales $105 to $110 million GAAP SG&A Expense $118 to $128 million GAAP R&D Expense $9 to $14 million Non-GAAP SG&A Expense $100 to $110 million Non-GAAP R&D Expense $7 to $12 million GAAP Net Loss ($8) to ($18) million Non-G
Slide 16: Full-Year 2018 Financial Guidance
Full-Year 2018 Financial Guidance* 2018 Guidance Neurology Franchise Net Sales $105 to $110 million GAAP SG&A Expense $118 to $128 million GAAP R&D Expense $9 to $14 million Non-GAAP SG&A Expense $100 to $110 million Non-GAAP R&D Expense $7 to $12 million GAAP Net Loss ($8) to ($18) million Non-GAAP
Slide 17: Note Regarding Use of GAAP and Non-GAAP Financial Measures
18 Note Regarding Use of GAAP and Non-GAAP Financial Measures To supplement our financial results presented on a U.S. generally accepted accounting principles (GAAP) basis, we have included information about non-GAAP adjusted EBITDA and other non-GAAP financial measures as useful operating metrics.
Slide 18: Non-GAAP Reconciliation
19 Non-GAAP Reconciliation (in millions) (unaudited) (5) Twelve Months Ended December 31, 2017 2016 2018 (unaudited) GAAP net earnings / (loss) (102,496) $ (88,720) $ 12,776 $ Pharmacy benefit manager dispute settlement 4,742 - - Commercialization agreement revenue (1) - - (49,288) Commercialization
Slide 19: Non-GAAP Reconciliation
20 Non-GAAP Reconciliation (in millions) (unaudited) For the six months ended 2016 2017 June 30, 2018 GAAP as reported 204,498 $ 195,695 $ 60,341 $ Contingent consideration related to product acquisitions 120 7,708 541 Stock based compensation (16,633) (12,157) (4,849) Expenses for opioid-related li
Slide 20: Full-Year 2018 Non-GAAP Guidance Reconciliation
21 Full-Year 2018 Non-GAAP Guidance Reconciliation (in millions) (unaudited) Low End High End Low End High End Low End High End GAAP ($8) ($18) $9 $14 $118 $128 Specified Items (2) $153 $173 ($2) ($2) ($18) ($18) Non-GAAP $145 $155 $7 $12 $100 $110 (2) For purposes of this forward-looking reconcilia
Slide 21: Full-Year 2018 Non-GAAP Guidance Reconciliation
Full-Year 2018 Non-GAAP Guidance Reconciliation (in millions) (unaudited) Full Year 2018 Guidance Earnings" R&D SG&A Low End High End Low End High End Low End High End Cod ($8) ($18) $9 $14 sus $128 Specified Items $153 $173 ($2) ($2) ($18) (18) Non-GAAP. $145 $155 $7 $12 $100 $110 (2) GAAP Earnings
Slide 22: Assertio September 2018
/SSSSERTIO= September 2018
Assertio Therapeutics — Investor Presentation (September 2018) on 6ix